Hinge Health, Inc.

Hinge Health, Inc.

HNGE·NYSE

$58.66

+6.6%
HealthcareMedical - Healthcare Information Services

Hinge Health, Inc. develops health care software for joint and muscle health. The company designs its platform to address a musculoskeletal care, acute injury, chronic pain, and post-surgical rehabilitation. It also provides various administrative and operations support services. The company was founded in 2012 and is headquartered in San Francisco, California.

At a Glance

Live Snapshot
Market Cap$4.54B
EPS-5.3600
P/E Ratio-6.96
Earnings Date08/04/2026
hnge

Hinge Health, Inc. Street Expectations Map

HNGE · NYSE

Wall Street analysts project that HNGE stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 65.82, with estimates ranging from a low of 45.00 to a high of 95.00.

Lowest Target
45.00
-23.29%
Consensus Target
65.82
12.21%
Highest Target
95.00
61.95%

The consensus 1-year price target stands at 65.82, with estimates ranging from a low of 45.00 to a high of 95.00.

Analyst Consensus Analysis

Upside Potential

+12.2%

Moderate upside. Analysts expect positive returns but with limited margin of safety. Consider entry timing.

Analyst Agreement

76.0% spread

High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.

Risk-Reward Profile

2.66x

Favorable risk-reward. Potential upside significantly exceeds downside risk, offering asymmetric return profile attractive for risk-tolerant investors.

Analyst Conviction

Low

High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.

Market Sentiment Insight

Extreme uncertainty: Massive dispersion in price targets reflects fundamental disagreement on business trajectory. This could signal transformation, disruption, or complex valuation—requires deep sector expertise and contrarian mindset.

hnge

Hinge Health, Inc. Forward Estimates of Revenue

HNGE · NYSE
Latest Revenue
587.86M
FY 2025
Avg Estimate
801.58M
FY 2026
Estimate Range
799.23M - 805.47M
Analyst Spread

Forward Growth Analysis

Projected Growth+36.4%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage12 Analysts

Good analyst coverage ensures reliable estimates with diverse professional perspectives.

Estimate Spread1%

Narrow estimate range signals strong analyst consensus and predictable business outlook.

OutlookStrong

Positive analyst consensus with strong growth expectations and forecast confidence.

Key Insight

Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.

hnge

Hinge Health, Inc. Forward Estimates of Net Income

HNGE · NYSE
Latest Net Income
-528.26M
FY 2025
Avg Estimate
194.43M
FY 2026
Estimate Range
167.93M - 220.92M
Analyst Spread

Forward Growth Analysis

Projected Growth+136.8%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage12 Analysts

Good analyst coverage ensures reliable estimates with diverse professional perspectives.

Estimate Spread27%

Moderate uncertainty in forecasts—typical for companies with evolving business models.

OutlookPositive

Generally favorable outlook with reasonable growth prospects and analyst support.

hnge

Hinge Health, Inc. Forward Estimates of EPS

HNGE · NYSE
Latest EPS
-5.36
FY 2025
Avg Estimate
$2.50
FY 2026
Estimate Range
$2.06 - $2.70
Analyst Spread

Forward Growth Analysis

Projected Growth+146.7%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage9 Analysts

Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread26%

Moderate uncertainty in forecasts—typical for companies with evolving business models.

OutlookPositive

Generally favorable outlook with reasonable growth prospects and analyst support.

hnge

Hinge Health, Inc. Forward Estimates of EBIT

HNGE · NYSE
Latest EBIT
-546.37M
FY 2025
Avg Estimate
-381.75M
FY 2026
Estimate Range
-383.60M - -380.63M
Analyst Spread

Forward Growth Analysis

Projected Growth+30.1%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage12 Analysts

Good analyst coverage ensures reliable estimates with diverse professional perspectives.

Estimate Spread1%

Narrow estimate range signals strong analyst consensus and predictable business outlook.

OutlookStrong

Positive analyst consensus with strong growth expectations and forecast confidence.

Key Insight

Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.

hnge

Hinge Health, Inc. Forward Estimates of EBITDA

HNGE · NYSE
Latest EBITDA
-541.24M
FY 2025
Avg Estimate
-375.87M
FY 2026
Estimate Range
-377.69M - -374.76M
Analyst Spread

Forward Growth Analysis

Projected Growth+30.6%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage12 Analysts

Good analyst coverage ensures reliable estimates with diverse professional perspectives.

Estimate Spread1%

Narrow estimate range signals strong analyst consensus and predictable business outlook.

OutlookStrong

Positive analyst consensus with strong growth expectations and forecast confidence.

Key Insight

Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.

hnge

Hinge Health, Inc. Forward Estimates of SG&A Expense

HNGE · NYSE
Latest SG&A Expense
646.46M
FY 2025
Avg Estimate
642.26M
FY 2026
Estimate Range
640.38M - 645.38M
Analyst Spread

Forward Growth Analysis

Projected Growth-0.6%

Declining expectations indicate headwinds—investigate whether temporary or structural issues.

Analyst Coverage12 Analysts

Good analyst coverage ensures reliable estimates with diverse professional perspectives.

Estimate Spread1%

Narrow estimate range signals strong analyst consensus and predictable business outlook.

OutlookPositive

Generally favorable outlook with reasonable growth prospects and analyst support.

hnge

Hinge Health, Inc. Insider Positioning

HNGE · NYSE

During the last 12 months, insiders have sold $47.67M worth of HNGE shares, with no buying activity reported.

3 Months

Bought

0

0.00

Sold

376.0K

18.69M

Net Activity

-18.7M

-$18.69M

3-6 Months

Bought

0

0.00

Sold

483.6K

21.73M

Net Activity

-21.7M

-$21.73M

6-9 Months

Bought

0

0.00

Sold

152.8K

7.25M

Net Activity

-7.3M

-$7.25M

9-12 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

Top Buyers

No buying activity

Top Sellers

1
PDA

Perez Daniel Antonio

Director, 10 Percent Owner, Officer: Ceo & Co-Founder

600.3K shares5 transactions

$28.45M

2
MGM

Mecklenburg Gabriel M.I.

Director, Other: Exec. Chairman & Co-Founder

215.1K shares4 transactions

$9.86M

3
IHGL

Insight Holdings Group, Llc

10 Percent Owner

131.1K shares1 transactions

$6.26M

4
BJ

Budge James

Officer: Chief Financial Officer

37.2K shares6 transactions

$1.81M

5
PJ

Pursley James

Officer: President

22.9K shares2 transactions

$1.03M

Insider Activity Analysis

Net Insider Sentiment

Bearish

Strong bearish signal with $47.67M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.

Buy/Sell Ratio

0.00:1

Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.

Recent Trend (3 Months)

$18.69M

Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.

Insider Participation

High Selling

5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.

Insider Activity Insight

Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.